GHRP-6 vs Sermorelin

Ghrelin receptor agonist; stimulates pituitary GH release and increases appetite via hypothalamic ghrelin pathways

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a) in pituitary somatotrophs and the hypothalamus, stimulating GH release through a mechanism that is synergistic with but distinct from endogenous growth hormone-releasing hormone (GHRH). Like other GHRP-class peptides, it engages hypothalamic arcuate nucleus circuits to potentiate GHRH-driven GH pulses and partially suppress somatostatin inhibitory tone; it was among the first GHRP-class compounds characterized pharmacologically and has been used extensively as a research tool for probing the GH secretory axis. Clinical studies have demonstrated dose-dependent GH release following GHRP-6 administration in human subjects, and the GHRP pharmacological class has been characterized across multiple studies documenting pituitary and hypothalamic mechanisms of action. GHRP-6 is not FDA-approved for any indication; it has been studied as a pharmacological tool and provocative GH stimulation agent but has not been evaluated for safety or efficacy in performance enhancement or muscle building outside research protocols. GHRP-6 dosage in research contexts: studies have used subcutaneous and intravenous doses typically in the range of 100–300 mcg per injection. In research protocols, GHRP-6 is often administered 2–3 times daily — before meals, before training, or before sleep — to leverage the body's natural GH pulse windows. GHRP-6 produces a pronounced appetite stimulation effect (a direct ghrelin-mimetic consequence) that is stronger than what is observed with more selective GHRPs such as ipamorelin; this characteristic is relevant to research contexts studying GH secretion alongside energy intake regulation. GHRP-6 vs GHRP-2: both are non-selective GHRPs producing GH alongside cortisol and prolactin co-stimulation, but GHRP-6 is noted for more pronounced ghrelin-like appetite stimulation, while GHRP-2 produces greater GH output per unit dose in some comparative studies. Neither offers the selectivity profile of ipamorelin, which emerged from subsequent GHRP research specifically to reduce off-target hormonal effects. GHRP-6 is administered by subcutaneous injection following reconstitution with bacteriostatic water. Providers offering GHRP-class secretagogues are listed in the PeptideBase directory.

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion in a physiological pattern that preserves the natural hypothalamic-pituitary feedback axis — contrasting with direct GH administration. Downstream IGF-1 elevation mediates many of its body composition, tissue-repair, and sleep quality effects.

Sermorelin acetate is a synthetic 29-amino-acid peptide (GHRH(1-29)NH2) corresponding to the biologically active N-terminal fragment of endogenous growth hormone-releasing hormone, developed as a prescription pharmaceutical to stimulate endogenous GH secretion from the pituitary gland as a diagnostic and therapeutic agent for GH deficiency. Sermorelin acts on pituitary somatotrophs via GHRH receptors to stimulate pulsatile GH release, preserving the natural feedback regulation of the GH axis — an advantage over direct exogenous GH administration — and multiple randomized controlled trials have established its pharmacokinetic and pharmacodynamic profile in populations with GH insufficiency including post-irradiation hypopituitarism. The compound received FDA approval as Geref (Serono) for diagnosis and treatment of GH deficiency in children; approval was voluntarily withdrawn by the manufacturer in 2008 for commercial rather than safety reasons, leaving the underlying human evidence base intact, and compounded sermorelin has since been widely used off-label in adult anti-aging and hormone optimization practice. Sermorelin is currently available only through compounding pharmacies under prescriber supervision; it is not FDA-approved for any current indication, and its use in adults represents off-label prescribing outside the regulatory framework established by its original pediatric approval. Sermorelin is available through telehealth platforms and hormone optimization clinics across the United States and is dispensed by compounding pharmacies under licensed prescriber supervision. Patients searching for sermorelin providers near them or via telehealth can use the PeptideBase directory to browse verified clinics and telehealth platforms offering sermorelin by location. Sermorelin bodybuilding and anti-aging research contexts have driven its widespread compounded use in adults, though these applications are off-label and outside the original pediatric approval framework. Sermorelin near me: sermorelin is available through licensed anti-aging clinics, hormone health practices, and telehealth platforms that specialize in growth hormone axis support. Because sermorelin requires a prescription, access involves a clinical consultation — many providers now offer this remotely via telehealth, eliminating the need for in-person visits. For those searching for sermorelin providers near them, PeptideBase maintains a directory of verified clinics and telehealth platforms offering sermorelin protocols across the United States. Sermorelin and ipamorelin together: yes, sermorelin and ipamorelin are frequently combined in clinical research and compounded hormone optimization protocols. The two peptides act on different receptors — sermorelin on GHRH receptors (stimulating the GHRH pathway) and ipamorelin on ghrelin receptors (GHS-R1a) — and their mechanisms are complementary rather than redundant. Combining a GHRH analog like sermorelin with a GHRP like ipamorelin produces synergistic GH release, consistent with the well-established pharmacological principle that GHRH and GH secretagogues act additively at the pituitary. Ipamorelin is specifically valued in this combination for its selectivity — it stimulates GH without the cortisol or prolactin co-stimulation that characterizes less selective GHRPs such as GHRP-2 or GHRP-6. The sermorelin + ipamorelin combination (and its extension, the sermorelin + CJC-1295 + ipamorelin triple protocol) is among the most commonly prescribed compounded GH secretagogue regimens in anti-aging and hormone optimization practice. Providers offering combination GH secretagogue protocols are listed in the PeptideBase directory.